NextCure Stock Price - NXTC

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
NextCure Inc NXTC NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.81 -2.16% 36.61 34.00 38.6965 36.23 37.42 00:00:05
Bid Price Ask Price Spread Spread % News
30.50 46.00 15.50 33.7% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,435 202,543 $ 36.63 $ 7,419,738 214,867 13.86 - 109.00
Last Trade Time Type Quantity Stock Price Currency
16:56:07 average 4,162 $ 36.61 USD

NextCure Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 1.01B 27.51M -1.60 - 26.86M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

NextCure News

Loading Messages....

Latest NXTC Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NXTC Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week34.3739.7530.0233.99201,8232.246.52%
1 Month40.2045.1528.2937.57231,988-3.59-8.93%
3 Months54.7561.0028.2944.91230,841-18.14-33.13%
6 Months35.47109.0023.6853.87386,7661.143.21%
1 Year15.55109.0013.8649.41255,31321.06135.43%
3 Years15.55109.0013.8649.41255,31321.06135.43%
5 Years15.55109.0013.8649.41255,31321.06135.43%

NextCure Description

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is a immunomedicine against a immunomodulatory receptor called Siglec-15, or S15.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.